Cat.NO.:A252966 Purity:98%
Product Details of [ 1000343-69-0 ]
CAS No. : | 1000343-69-0 |
Formula : |
C8H7BrN2 |
M.W : |
211.06
|
SMILES Code : | CC1=CC2=C(NN=C2)C=C1Br |
MDL No. : | MFCD09026997 |
InChI Key : | YLLZDOJZLKUKEA-UHFFFAOYSA-N |
Pubchem ID : | 24729264 |
Safety of [ 1000343-69-0 ]
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H332-H335 |
Precautionary Statements: | P261-P280-P305+P351+P338 |
Computational Chemistry of [ 1000343-69-0 ] Show Less
Physicochemical Properties
Num. heavy atoms | 11 |
Num. arom. heavy atoms | 9 |
Fraction Csp3 | 0.12 |
Num. rotatable bonds | 0 |
Num. H-bond acceptors | 1.0 |
Num. H-bond donors | 1.0 |
Molar Refractivity | 48.76 |
TPSA ?
Topological Polar Surface Area: Calculated from |
28.68 Ų |
Lipophilicity
Log Po/w (iLOGP)?
iLOGP: in-house physics-based method implemented from |
1.55 |
Log Po/w (XLOGP3)?
XLOGP3: Atomistic and knowledge-based method calculated by |
2.61 |
Log Po/w (WLOGP)?
WLOGP: Atomistic method implemented from |
2.63 |
Log Po/w (MLOGP)?
MLOGP: Topological method implemented from |
2.19 |
Log Po/w (SILICOS-IT)?
SILICOS-IT: Hybrid fragmental/topological method calculated by |
3.15 |
Consensus Log Po/w?
Consensus Log Po/w: Average of all five predictions |
2.43 |
Water Solubility
Log S (ESOL):?
ESOL: Topological method implemented from |
-3.4 |
Solubility | 0.0844 mg/ml ; 0.0004 mol/l |
Class?
Solubility class: Log S scale |
Soluble |
Log S (Ali)?
Ali: Topological method implemented from |
-2.86 |
Solubility | 0.29 mg/ml ; 0.00137 mol/l |
Class?
Solubility class: Log S scale |
Soluble |
Log S (SILICOS-IT)?
SILICOS-IT: Fragmental method calculated by |
-4.16 |
Solubility | 0.0147 mg/ml ; 0.0000697 mol/l |
Class?
Solubility class: Log S scale |
Moderately soluble |
Pharmacokinetics
GI absorption?
Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
BBB permeant?
BBB permeation: according to the yolk of the BOILED-Egg |
Yes |
P-gp substrate?
P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
CYP1A2 inhibitor?
Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
Yes |
CYP2C19 inhibitor?
Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
CYP2C9 inhibitor?
Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
CYP2D6 inhibitor?
Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
CYP3A4 inhibitor?
Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
Log Kp (skin permeation)?
Skin permeation: QSPR model implemented from |
-5.73 cm/s |
Druglikeness
Lipinski?
Lipinski (Pfizer) filter: implemented from |
0.0 |
Ghose?
Ghose filter: implemented from |
None |
Veber?
Veber (GSK) filter: implemented from |
0.0 |
Egan?
Egan (Pharmacia) filter: implemented from |
0.0 |
Muegge?
Muegge (Bayer) filter: implemented from |
0.0 |
Bioavailability Score?
Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
Medicinal Chemistry
PAINS?
Pan Assay Interference Structures: implemented from |
0.0 alert |
Brenk?
Structural Alert: implemented from |
0.0 alert: heavy_metal |
Leadlikeness?
Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
Synthetic accessibility?
Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
1.43 |
Application In Synthesis of [ 1000343-69-0 ]
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
- Downstream synthetic route of [ 1000343-69-0 ]
[ 1000343-69-0 ] Synthesis Path-Downstream 1~1
- 1
[ 1000343-69-0 ]
[ 1074-40-4 ]
- 6-bromo-1-(6-chloro-2-methoxypyrimidin-4-yl)-5-methyl-1H-indazole [ No CAS ]
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
57.3% | With caesium carbonate; In N,N-dimethyl-formamide; at 120.0℃; for 1.5h;Microwave irradiation; | 6-Bromo-5-methyl-1 H-indazoie (50 mg, 0.237 mmol) and 4,6-dichloro-2-methoxypyrimidmne (127 mg, 0.711 mmol) was dissolved in DMF (3 mL), Cs2CO3 (154 mg, 0.474 mmol) was added and the mixture was stirrd at 120 °C for 1.5 h under microwave irradiation. Water (20 mL) and EtOAc (50 mL) were added to the reaction mixture. The layers were seperated and the aqueous layer was extracted by EtOAc (30 mL). The combined organic layers waswashed with saturated aqueous NaCI (50 mL x 2 times), dried over anhydrous Na2SO4 and then concentrated under the reduced pressure. The residue was purified by normal phase chromatography (ISCO, 24g column, PE: EtOAc= 100:0 –> 80:20) to afford 6-bromo-1-(6- chloro-2-methoxypyrimidin-4-yI)-5-methyl-1 H-indazole (48 mg, 0.136 mmol, 57.3 percent yield) as a white solid.LCMS: (mobile phase: 5-95percent acetonitrile), Rt = 4.47 mm in 5 mm; MS Calcd: 352; MSFound: 353 [M+1].1H NMR (DMSO-d6): 8.92 (s, 1H), 8.59 (s, 1H), 7.93 (s, IH), 7.60 (s, 1H), 4.08 (s, 3H)(Note:a CH3 peak is masked by the solvent DMSO) |
Reviews
There are no reviews yet.